J. V. van Veldhoven

发表

2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists.

A. IJzerman, T. Mulder-Krieger, H. de Vries, 2008, Journal of medicinal chemistry.

The role of the C-terminus of the human hydroxycarboxylic acid receptors 2 and 3 in G protein activation using Gα-engineered yeast cells.

A. IJzerman, J. V. van Veldhoven, Rongfang Liu, 2016, European journal of pharmacology.

False positives in a reporter gene assay: identification and synthesis of substituted N-pyridin-2-ylbenzamides as competitive inhibitors of firefly luciferase.

A. IJzerman, L. Heitman, J. V. van Veldhoven, 2008, Journal of medicinal chemistry.

Allosteric Modulation of Kv11.1 (hERG) Channels Protects Against Drug-Induced Ventricular Arrhythmias

A. IJzerman, L. Heitman, J. V. van Veldhoven, 2016, Circulation. Arrhythmia and electrophysiology.

Synthesis and biological evaluation of negative allosteric modulators of the Kv11.1(hERG) channel.

A. IJzerman, L. Heitman, J. V. van Veldhoven, 2015, European journal of medicinal chemistry.

Affinity and kinetics study of anthranilic acids as HCA2 receptor agonists.

A. IJzerman, J. V. van Veldhoven, Rongfang Liu, 2015, Bioorganic & medicinal chemistry.

Novel 3,6,7-substituted pyrazolopyrimidines as positive allosteric modulators for the hydroxycarboxylic acid receptor 2 (GPR109A).

A. IJzerman, J. V. van Veldhoven, J. Brussee, 2012, Journal of medicinal chemistry.

Pyrrolone Derivatives as Intracellular Allosteric Modulators for Chemokine Receptors: Selective and Dual-Targeting Inhibitors of CC Chemokine Receptors 1 and 2

A. IJzerman, L. Heitman, J. V. van Veldhoven, 2018, Journal of medicinal chemistry.

Dual-Point Competition Association Assay

A. IJzerman, T. Mulder-Krieger, D. Guo, 2013, Journal of biomolecular screening.

Structure-activity relationships of trans-substituted-propenoic acid derivatives on the nicotinic acid receptor HCA2 (GPR109A).

A. IJzerman, J. V. van Veldhoven, J. Brussee, 2011, Bioorganic & medicinal chemistry letters.

Crystal Structure and Subsequent Ligand Design of a Nonriboside Partial Agonist Bound to the Adenosine A2A Receptor

G. V. van Westen, A. IJzerman, E. Segala, 2021, Journal of medicinal chemistry.

Protection from Myocardial Ischemia/Reperfusion Injury by a Positive Allosteric Modulator of the A3 Adenosine Receptor

K. Jacobson, A. IJzerman, J. V. van Veldhoven, 2012, Journal of Pharmacology and Experimental Therapeutics.

A new hERG allosteric modulator rescues genetic and drug‐induced long‐QT syndrome phenotypes in cardiomyocytes from isogenic pairs of patient induced pluripotent stem cells

Adriaan P IJzerman, Karl-Ludwig Laugwitz, Zhiyi Yu, 2016, EMBO molecular medicine.

Targeting the Kv11.1 (hERG) channel with allosteric modulators. Synthesis and biological evaluation of three novel series of LUF7346 derivatives.

C. Mummery, A. IJzerman, J. V. van Veldhoven, 2020, European journal of medicinal chemistry.

A new generation of adenosine receptor antagonists: from di- to trisubstituted aminopyrimidines.

A. IJzerman, T. Mulder-Krieger, J. V. van Veldhoven, 2008, Bioorganic & medicinal chemistry.

Synthesis and Pharmacological Evaluation of Triazolopyrimidinone Derivatives as Noncompetitive, Intracellular Antagonists for CC Chemokine Receptors 2 and 5

A. IJzerman, L. Heitman, J. V. van Veldhoven, 2019, Journal of medicinal chemistry.

Predicting Binding Affinities for GPCR Ligands Using Free-Energy Perturbation

Woody Sherman, Adriaan P. IJzerman, Robert Abel, 2016, ACS omega.

Adenosine A2B Receptor Agonism Inhibits Neointimal Lesion Development After Arterial Injury in Apolipoprotein E–Deficient Mice

A. IJzerman, H. de Vries, J. V. van Veldhoven, 2012, Arteriosclerosis, thrombosis, and vascular biology.

A series of 2,4-disubstituted quinolines as a new class of allosteric enhancers of the adenosine A3 receptor.

Thea Mulder-Krieger, Johannes Brussee, A. IJzerman, 2009, Journal of medicinal chemistry.

Structure–Affinity Relationships and Structure–Kinetics Relationships of Pyrido[2,1-f]purine-2,4-dione Derivatives as Human Adenosine A3 Receptor Antagonists

A. IJzerman, L. Heitman, J. V. van Veldhoven, 2017, Journal of medicinal chemistry.

Development of Covalent Ligands for G Protein-Coupled Receptors: A Case for the Human Adenosine A3 Receptor

A. IJzerman, L. Heitman, J. V. van Veldhoven, 2019, Journal of medicinal chemistry.

Development of subtype-selective covalent ligands for the adenosine A2B receptor by tuning the reactive group.

A. IJzerman, L. Heitman, J. V. van Veldhoven, 2022, RSC medicinal chemistry.

A new generation of adenosine receptor antagonists: from di- to trisubstituted aminopyrimidines.

A. IJzerman, T. Mulder-Krieger, J. V. van Veldhoven, 2008, Bioorganic & medicinal chemistry.

Structure-Affinity Relationships (SARs) and Structure-Kinetics Relationships (SKRs) of Kv11.1 Blockers.

Adriaan P IJzerman, Zhiyi Yu, A. IJzerman, 2015, Journal of medicinal chemistry.

Protection from Myocardial Ischemia/Reperfusion Injury by a Positive Allosteric Modulator of the A3 Adenosine Receptor

K. Jacobson, A. IJzerman, J. V. van Veldhoven, 2012, Journal of Pharmacology and Experimental Therapeutics.

Label-free detection of prostaglandin transporter (SLCO2A1) function and inhibition: insights by wound healing and TRACT assays

L. Heitman, J. V. van Veldhoven, Tamara A. M. Mocking, 2024, Frontiers in pharmacology.

Labeling of CC Chemokine Receptor 2 with a Versatile Intracellular Allosteric Probe.

L. Heitman, J. V. van Veldhoven, Natalia V. Ortiz Zacarías, 2024, ACS chemical biology.